| (Values in U.S. Thousands) | Jun, 2026 | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 |
| Sales | 6,900 | 7,550 | 12,210 | 37,160 | 18,190 |
| Sales Growth | -8.61% | -38.17% | -67.14% | +104.29% | +51.21% |
| Net Income | -21,820 | -17,770 | -26,320 | 590 | -23,740 |
| Net Income Growth | -22.79% | +32.48% | -4,561.02% | +102.49% | -30.94% |
Cellectis S.A. ADR (CLLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.
Fiscal Year End Date: 12/31